Lapatynib w leczeniu zaawansowanego, HER2-dodatniego raka piersi Case report

##plugins.themes.bootstrap3.article.sidebar##

PDF (English)


Opublikowane: sie 17, 2017
DOI: https://doi.org/10.24292/01.OR.170817
Słowa kluczowe:
zaawansowany rak piersi, receptor naskórkowego czynnika wzrostu typu 2, HER2, lapatynib, kapecytabina

##plugins.themes.bootstrap3.article.main##

Małgorzata Kuc-Rajca
1. Department of Oncology, Otwock European Health Center. 2. Second Urology Clinic, Center of Postgraduate Medical Education
Anna Walaszkowska-Czyż
Department of Oncology, Otwock European Health Center

Abstrakt

Rak piersi z nadekspresją receptora HER2 lub amplifikacją jego genu stanowi ok. 20% wszystkich zachorowań, cechuje się on bardziej agresywnym przebiegiem i gorszym rokowaniem. Nowe leki ukierunkowane na receptor HER2, takie jak: lapatynib, pertuzumab czy trastuzumab emtanzyna, poprawiły skuteczność leczenia zaawansowanego raka piersi. W artykule omówiono rolę lapatynibu w terapii nakierowanej na szlak receptora HER oraz opisano sekwencję leczenia 2 pacjentek z zaawansowanym rakiem piersi HER2-dodatnim.

Pobrania

Dane pobrania nie są jeszcze dostepne

##plugins.generic.paperbuzz.metrics##

##plugins.generic.paperbuzz.loading##

##plugins.themes.bootstrap3.article.details##

Jak cytować
1.
Kuc-Rajca M, Walaszkowska-Czyż A. Lapatynib w leczeniu zaawansowanego, HER2-dodatniego raka piersi. OncoReview [Internet]. 17 sierpień 2017 [cytowane 27 kwiecień 2025];7(3(27):144-9. Dostępne na: https://journalsmededu.pl/index.php/OncoReview/article/view/467
Numer
Tom 7 Nr 3(27) (2017)
Dział
QUALITY OF LIFE IN ONCOLOGY
Creative Commons License

Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne 4.0 Międzynarodowe.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

Bibliografia

1. Brufsky A. Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care. Am J Clin Oncol 2010; 33: 186-195.
2. Mariani G, Fasolo A, De Benedictis E. Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol 2009; 6: 93-104.
3. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743.
4. Cameron D, Casey M, Press M et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res. Treat 2008; 112: 533-543.
5. Capri G, Chang J, Chen S et al. An open-label expanded access study of lapatinib and capecitabine in patients with HER2 overexpressing locally advanced or metastatic breast cancer. Ann Oncol 2010; 21: 474-480.
6. Zhou X, Cella D, Cameron D et al. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat 2009; 117: 577-589.
7. Perez EA, Koehler M, Byrne J et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008; 83: 679-686.
8. Sendur MA, Aksoy S, Altundag K. Cardiotoxicity of novel HER2-targeted therapies. Curr. Med Res Opin 2013; 29(8): 1015-1024.
9. Johnston S, Pippen J, Pivot X et al. Lapatinib combined with letrozol versus letrozol and placebo as first line therapy for postmenopausal hormone-receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27: 5538-5546.
10. Bendell J, Domchek S, Burstein HJ et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97: 2972-2977.
11. Lai R, Dang CT, Malkin MG et al. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 2004; 15: 810-816.
12. Stemmler HJ, Kahlert S, Siekiera W. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 2006; 15: 219-225.
13. Duchnowska R, Dziadziuszko R, Czartoryska-Arłukowicz B et al. Risk factors for brain relapse in HER2-positive metastatic breast cancer patients. Breast Cancer Res Treat 2009; 117: 297-303.
14. Burstein HJ, Lieberman G, Slamon DJ. Isolated central nervous system metastases in patients with HER2 overexpressing advanced breast cancer treated with first-line trastuzumab based therapy. Ann Oncol 2005; 16: 1772-1777.
15. Lin NU, Diéras V, Paul D et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009; 15: 1452-1459.
16. Boccardo F, Kaufman B, Baselga J et al. Evaluation of lapatinib plus capecitabine in patients with brain metastases from HER2+ breast cancer enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d’Utilisation (ATU) ASCO Conference, May 30–June 3, 2008.
17. Sutherland S, Ashley S, Miles D et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases — the UK experience. Br J Cancer 2010; 102: 995-1002.
18. Bachelot TD, Romieu G, Campone M et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 2013; 14(1): 64-71.